Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (15,106,000)	$ (11,953,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,221,000	141,000
Depreciation expense	54,000	20,000
Reserve for uncollectible accounts		167,000
Gain on disposal of assets	(45,000)
Changes in assets and liabilities:
Prepaid expenses and other current assets	(1,689,000)	575,000
Operating lease right-of-use assets	666,000	648,000
Accounts payable	141,000	(85,000)
Accrued expenses and other current liabilities	150,000	1,278,000
Operating lease liabilities	(667,000)	(627,000)
Net cash used in operating activities	(15,275,000)	(9,836,000)
Cash flows from investing activities:
Purchases of property and equipment	(674,000)	(131,000)
Net cash used in investing activities	(674,000)	(131,000)
Cash flows from financing activities:
Payment of offering costs	(2,383,000)	(26,000)
Proceeds from initial public offering, net of underwriting discount	59,892,000
Proceeds from exercise of stock options	1,000	109,000
Net cash provided by financing activities	87,696,000	83,000
Net increase (decrease) in cash and cash equivalents	71,747,000	(9,884,000)
Cash and cash equivalents and restricted cash, beginning of period	10,137,000	24,217,000
Cash and cash equivalents and restricted cash, end of period	81,884,000	14,333,000
Supplemental disclosure of non-cash financing and investing activities:
Property and equipment purchases included in accounts payable	17,000
Conversion of redeemable convertible preferred stock	160,227,000
Accretion of redeemable convertible preferred stock to redemption value	115,000	234,000
Right-of-use asset obtained in exchange of operating lease obligation	13,000	4,046,000
Deferred offering costs included in accounts payable and accrued expense		$ 144,000
Series C
Cash flows from financing activities:
Proceeds from the sale of Series C redeemable convertible preferred stock	30,392,000
Payment of offering costs	(206,000)
Supplemental disclosure of non-cash financing and investing activities:
Allocation of Series C redeemable convertible preferred stock to common stock warrant	$ 740,000